ANTONIO JULIÁ, M.D.; LORENZO FONT, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In Barton and Conrad's article (1) in the February 1979 issue there is an implication that hepatitis may have a beneficial effect in acute myelogenous leukemia. Several letters expressed concern for the conclusions in this article but did not provide evidence against the reasoning.
We decided to review our own experience to ascertain the effect of the increase in serum glutamic-oxalacetic transaminase (SGOT) on survival in patients with acute myelogenous leukemia and compared the results with those obtained by Barton and Conrad.
We reviewed the records of 52 adult patients, seen at our institution during the last
JULIÁ A, FONT L. Hepatitis and Leukemia. Ann Intern Med. ;93:780. doi: 10.7326/0003-4819-93-5-780
Download citation file:
Published: Ann Intern Med. 1980;93(5):780.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use